The interaction of a glycosaminoglycan, heparin, with HIV-1 major envelope glycoprotein.
We demonstrate in vitro the occurrence of a specific but low-affinity interaction between soluble tetrameric rgp160 or soluble monomeric or tetrameric rgp120 and heparin-agarose (HA). This interaction is saturable, pH and temperature-dependent, and can be inhibited by soluble heparin, but not by soluble dextran. In buffer supplemented with 10 mM CaCl2, the C50 of soluble heparin, i.e., the concentration of soluble heparin which leads to 50% inhibition of the binding of [125I]rgp160 or of [125I]rgp120 to HA, is 1.1 x 10(-4) disaccharidic molar concentration for rgp160 and 3.2 x 10(-4) dissacharidic molar concentration for rgp120, which indicates low-affinity interactions. Upon chromatography on HA, [125I]rgp160 is repeatedly eluted as a retarded fraction when compared to the elution volume of [125I]rgp160-soluble heparin complex. Under the same experimental conditions, [125I]rgp120 is also eluted, but as a less retarded fraction than [125I]rgp160. Taken together, these results suggest that, at least part of the described anti HIV-1 activity of heparin might be mediated by interaction with HIV-1 major envelope glycoprotein.
D003911:Dextrans / Q000494:pharmacology; D015686:Gene Products, env / Q000737:chemistry*; D015699:HIV Envelope Protein gp120 / Q000737:chemistry*; D019302:HIV Envelope Protein gp160; D006493:Heparin / Q000494:pharmacology*; D006863:Hydrogen-Ion Concentration; D007457:Iodine Radioisotopes; D011498:Protein Precursors / Q000737:chemistry*; D011994:Recombinant Proteins / Q000737:chemistry; D012685:Sepharose / Q000031:analogs & derivatives / Q000737:chemistry; D013696:Temperature
D003911:Dextrans; D015686:Gene Products, env; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D007457:Iodine Radioisotopes; D011498:Protein Precursors; D011994:Recombinant Proteins; C037405:heparin-sepharose; D006493:Heparin; D012685:Sepharose